Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients

Jordy C.G. van der Zwet, Valentina Cordo', Kirsten Canté-Barrett, Jules P.P. Meijerink

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

13 Citaten (Scopus)


In the last decade, tremendous progress in curative treatment has been made for T-ALL patients using high-intensive, risk-adapted multi-agent chemotherapy. Further treatment intensification to improve the cure rate is not feasible as it will increase the number of toxic deaths. Hence, about 20% of pediatric patients relapse and often die due to acquired therapy resistance. Personalized medicine is of utmost importance to further increase cure rates and is achieved by targeting specific initiation, maintenance or resistance mechanisms of the disease. Genomic sequencing has revealed mutations that characterize genetic subtypes of many cancers including T-ALL. However, leukemia may have various activated pathways that are not accompanied by the presence of mutations. Therefore, screening for mutations alone is not sufficient to identify all molecular targets and leukemic dependencies for therapeutic inhibition. We review the extent of the driving type A and the secondary type B genomic mutations in pediatric T-ALL that may be targeted by specific inhibitors. Additionally, we review the need for additional screening methods on the transcriptional and protein levels. An integrated ‘multi-omic’ screening will identify potential targets and biomarkers to establish significant progress in future individualized treatment of T-ALL patients.

Originele taal-2Engels
TijdschriftAdvances in Biological Regulation
StatusGepubliceerd - dec. 2019


Duik in de onderzoeksthema's van 'Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients'. Samen vormen ze een unieke vingerafdruk.

Citeer dit